Healthcare in the United Arab Emirates
暫譯: 阿拉伯聯合大公國的醫療保健

阿聯酋的醫療保健：變革之旅的全面洞察

這本在阿聯酋醫療保健歷史上首創的開放存取書籍，旨在成為各種利益相關者深入了解阿聯酋醫療保健環境的重要資源，涵蓋所有七個酋長國，並包括私營和公共健康系統。它系統性地探討了阿聯酋醫療政策、服務提供和創新演變的旅程，慶祝關鍵里程碑和成功故事，同時揭示持續存在的挑戰和未滿足的需求。

本書由來自阿聯酋各地的多元專家團隊撰寫，涵蓋初級護理、專科護理、預防醫學、公共衛生政策、監管框架、報銷系統、臨床研究、健康資訊學、健康經濟學、醫學教育、培訓和許可等領域的專業人士的貢獻。此外，它還探討了阿聯酋醫療保健領域中不斷演變的興趣領域，例如蓬勃發展的醫療旅遊產業以及日益增長的精準醫療和人工智慧的應用。

各章節不僅深入探討特定醫療學科面臨的挑戰，還提供對未來方向的戰略見解，勾勒出所需變革的清晰路線圖。本書還提出了一個前瞻性的藍圖，旨在未來50年內促進醫療保健部門的增長，以滿足健康長壽和基礎設施可持續性的國家優先事項。

這是第一本提供如此廣泛、深入分析阿聯酋醫療保健的綜合出版物。獲得著名的阿聯酋腫瘤學會和阿聯酋醫學會的認可，這是對理解和推進該地區醫療保健的重要貢獻。

無論您是醫療保健專業人士、政策制定者、學術學者還是投資者，本書都提供了有價值的觀點和可行的見解，讓您深入了解世界上最具活力的醫療保健系統之一。

Prof. Humaid Obaid Al-Shamsi is the Chief Executive Officer of Burjeel Cancer Institute in Abu Dhabi, UAE, President of the Emirates Oncology Society, Lead of the Gulf Cancer Society, Visiting Professor at Harvard Medical School at Harvard University, Full Professor of Oncology at the Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE, and an Adjunct Professor of Oncology at the College of Medicine, University of Sharjah. He is the first Emirati to be promoted as a professor in oncology in the UAE. He is also the Chairman for Colorectal Cancer in the MENA region, appointed by the prestigious National Comprehensive Cancer Network(R) in the USA. He is also the only member of the Lung Cancer Policy Network in the MENA region that aims to advance lung cancer research and screening globally. He is the Chairman of the Oncology and Hematology Fellowship Training Program for the National Institute for Health Specialties in the United Arab Emirates. He is the only member in GCC in the WIN Consortium, which is comprised of organizations representing all stakeholders in personalized cancer medicine globally.

He is board-certified in both internal medicine and oncology from the UK, USA (ABIM), and Canada (FRCPC). He has also been awarded the FRCP (Canada) in 2012, FRCP (London) in 2023, and FRCP (Glasgow) in 2024. He is the only physician in the UAE with a subspecialty fellowship certification and training in gastrointestinal oncology and the first Emirati to train and complete a clinical post-doctoral fellowship in palliative care. He was an assistant professor at the University of Texas MD Anderson Cancer Center between 2014 and 2017. He has published more than 160 peer-reviewed articles in JAMA Oncology, Lancet Oncology, Journal of Clinical Oncology, The Oncologist, BMC Cancer, and many others. His area of expertise includes precision oncology and cancer care in the UAE. In 2016, he published with his group from MD Anderson at the Journal of Clinical Oncology a study describing a new distinct subgroup of colorectal cancer, NON-V600 BRAF-mutated colorectal cancer. In 2022, he published the first book about cancer research in the UAE and also the first book about cancer in the Arab world, both of which were launched at Dubai Expo 2020. Cancer in the Arab World has been downloaded more than 500,000 times in its first 2 years of publication and is the ultimate source of cancer data in the Arab region. He also published the first comprehensive book, "Cancer Care in the United Arab Emirates," which is the first book in UAE history to document the cancer care in the UAE with many topics addressed for the first time. The book was also another success with over 100,000 downloads in the first 2 months of publication. He is passionate about advancing cancer care in the UAE and the GCC and has made significant contributions to cancer awareness and early detection for the public using social media platforms. He is considered the most followed oncologist in the world, with over half a million subscribers across his social media platforms (Instagram, Twitter, LinkedIn, and TikTok). In 2022, he was awarded the prestigious Feigenbaum Leadership Excellence Award from Sheikh Hamdan Smart University for his exceptional leadership and research, and he was also awarded the Sharjah Award for Volunteering. He was also named the Researcher of the Year in the UAE in 2020 and 2021 by the Emirates Oncology Society.

In May 2024, HH Sheikh Mansour bin Zayed Al Nahyan, Vice President of the United Arab Emirates, awarded him first place in the Emirati Talent Competitiveness Council (NAFIS) program for outstanding leadership in the private sector across all business and medical disciplines. In Feb 2025, Prof. Al Shamsi was awarded the "Sheikha Fatima bint Mubarak Family Awards" for being a successful role model in UAE society.

As a CEO of Burjeel Cancer Institute, Prof. Al Shamsi is leading the largest cancer network in the UAE with over 30 oncologists and hematologists and built the first paediatric bone marrow transplant program in the UAE. He secured the UAE's first European Society for Medical Oncology accreditation for a cancer center in the UAE at Burjeel Cancer Institute.

Beside his clinical and administrative duties, he is engaged in education and various levels of research training for medical trainees to enhance their clinical and research skills. He established the UAE's first hematology and oncology fellowship training program accredited by the UAE National Institute for Health Specialties at Burjeel Cancer Institute.

His mission is to advance cancer care in the UAE and the MENA region and make cancer care accessible to everyone in need around the globe.

哈馬德·奧拜德·阿爾沙姆西教授是阿布達比Burjeel癌症研究所的首席執行官，阿聯酋腫瘤學會的會長，海灣癌症協會的負責人，哈佛大學醫學院的訪問教授，拉斯阿爾哈伊瑪醫療與健康科學大學的腫瘤學全職教授，以及沙迦大學醫學院的腫瘤學兼任教授。他是阿聯酋首位晉升為腫瘤學教授的阿聯酋國籍人士。他還是美國國家綜合癌症網絡(R)任命的中東和北非地區結直腸癌主席。他也是中東和北非地區唯一的肺癌政策網絡成員，該網絡旨在推進全球肺癌研究和篩查。他是阿聯酋國家健康專業機構的腫瘤學和血液學獎學金培訓計劃的主席。他是海灣合作委員會中WIN聯盟的唯一成員，該聯盟由代表全球個性化癌症醫學所有利益相關者的組織組成。

他在英國、美國(ABIM)和加拿大(FRCPC)獲得內科和腫瘤學的董事會認證。他於2012年獲得FRCP(加拿大)，2023年獲得FRCP(倫敦)，2024年獲得FRCP(格拉斯哥)。他是阿聯酋唯一擁有腸胃腫瘤學亞專科獎學金認證和培訓的醫生，也是首位接受並完成緩和醫療臨床博士後獎學金的阿聯酋國籍人士。他曾於2014年至2017年擔任德克薩斯大學MD安德森癌症中心的助理教授。他在《JAMA Oncology》、《Lancet Oncology》、《Journal of Clinical Oncology》、《The Oncologist》、《BMC Cancer》等期刊上發表了超過160篇同行評審的文章。他的專業領域包括精準腫瘤學和阿聯酋的癌症護理。2016年，他與MD安德森的團隊在《Journal of Clinical Oncology》上發表了一項研究，描述了一種新的結直腸癌亞組，NON-V600 BRAF突變結直腸癌。2022年，他出版了阿聯酋首本關於癌症研究的書籍，以及阿拉伯世界首本關於癌症的書籍，這兩本書均在2020年迪拜博覽會上發布。《癌症在阿拉伯世界》在發行的前兩年內下載超過500,000次，成為阿拉伯地區癌症數據的終極來源。他還出版了第一本綜合性書籍《阿聯酋的癌症護理》，這是阿聯酋歷史上第一本記錄阿聯酋癌症護理的書籍，許多主題首次被提及。該書在發行的前兩個月內也取得了成功，下載量超過100,000次。他熱衷於推進阿聯酋和海灣合作委員會的癌症護理，並通過社交媒體平台對公眾進行癌症意識和早期檢測的宣傳。他被認為是全球最受關注的腫瘤學家，在他的社交媒體平台（Instagram、Twitter、LinkedIn和TikTok）上擁有超過50萬的訂閱者。2022年，他因其卓越的領導力和研究獲得了哈姆丹智能大學的Feigenbaum領導卓越獎，並獲得了沙迦志願服務獎。他還在2020年和2021年被阿聯酋腫瘤學會評選為阿聯酋年度研究人員。

在2024年5月，阿聯酋副總統曼蘇爾·本·扎耶德·阿爾納哈揚殿下在阿聯酋人才競爭委員會(NAFIS)計劃中授予他私營部門卓越領導的第一名。在2025年2月，阿爾沙姆西教授因在阿聯酋社會中成為成功的榜樣而獲得「謝赫·法蒂瑪·賓特·穆巴拉克家庭獎」。

作為Burjeel癌症研究所的首席執行官，阿爾沙姆西教授領導著阿聯酋最大的癌症網絡，擁有超過30名腫瘤學家和血液學家，並建立了阿聯酋首個兒童骨髓移植計劃。他為Burjeel癌症研究所獲得了阿聯酋首個歐洲醫學腫瘤學會的癌症中心認證。

除了臨床和行政職責外，他還參與醫療培訓生的教育和各級研究培訓，以提升他們的臨床和研究技能。他在Burjeel癌症研究所建立了阿聯酋首個由阿聯酋國家健康專業機構認證的血液學和腫瘤學獎學金培訓計劃。

他的使命是推進阿聯酋和中東北非地區的癌症護理，並使全球所有需要的人都能獲得癌症護理。